Clinical Results Presented for Trovagene's Urine-Based High-Risk HPV Assay.

SEATTLE, Aug. 25, 2014 -- Trovagene, Inc. (NASDAQ:  TROV), a developer of cell-free molecular diagnostics, announced today that results from two independent clinical studies were presented at the 29th International Papillomavirus (IPV) Conference. Results from both pilot studies consistently demonstrated that the Company's urine-based assay for the detection of high-risk HPV had high sensitivity (greater than 90%) for identifying women with high grade cervical intraepithelial neoplasia (CIN2/3). Assay performance was comparable to traditional HPV testing with commercially available tests in patient-matched cervical samples. In one of these studies, urine collection has been examined to establish standardization of urine as a clinical specimen for high-risk HPV testing.

Published: 25 August 2014
Written by Editor
Nasdaq   Project Update  
Read more: Trovagene Inc ( TROV )

Miraculins Executes Agreement for the Sale and Distribution of Up to $90 Million USD in Scout DS® Diabetes Screening Devices in China

Cachet Pharmaceutical Appointed as Exclusive Distributor for Mainland China

WINNIPEG, MANITOBA--(  Aug 14, 2014) - Miraculins Inc. (TSX VENTURE:MOM) ("Miraculins" or the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, today announces that it has executed a definitive agreement (the "Agreement") for the sale and distribution of Scout DS® diabetes screening devices into China with Catalyn Medical Technologies Limited ("Catalyn"), a privately-owned and Hong Kong based medical device import company. Cachet Pharmaceutical Co., Ltd. ("Cachet") has been co-appointed as the exclusive distributor of the Scout DS® devices in Mainland China by Miraculins and Catalyn.

Published: 14 August 2014
Written by Editor
New Product or Order   Up on News   Interesting News   TSXV  
Read more: Miraculins Inc ( MOM )

T2 Biosystems Announces Pricing of Initial Public Offering

LEXINGTON, Mass., Aug. 7, 2014 -- T2 Biosystems, Inc. today announced the pricing of its initial public offering of 5,200,000 shares of common stock at a public offering price of $11.00 per share, before underwriting discounts. All of the common stock is being offered by T2 Biosystems. In addition, T2 Biosystems has granted the underwriters a 30-day option to purchase up to an additional 780,000 shares of common stock from the company at the public offering price. The company's shares are expected to begin trading on the NASDAQ Global Market on August 7, 2014 under the ticker symbol "TTOO."

Goldman, Sachs & Co. and Morgan Stanley & Co. are acting as joint book-running managers for the offering. Leerink Partners and Janney Montgomery Scott are acting as co-managers.

Published: 07 August 2014
Written by Editor
Nasdaq   Up on News   New Listing  
Read more: T2 Biosystems Inc ( TTOO )

Miraculins Announces Publication of Peer-Reviewed Study That Demonstrates Scout DS(R) Is a Viable Alternative to Current Pre-Diabetes and Type 2 Diabetes Screening Methods

Study Shows Scout DS(R) detects abnormal glucose tolerance just as well as Fasting Plasma Glucose and HbA1c testing without blood draw or fasting

WINNIPEG, MANITOBA-- Miraculins Inc. (TSX VENTURE:MOM) ("Miraculins" or the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, today announces the publication of results from the ENGINE (Evaluation of a Noninvasive Diabetes Screening Device in Subjects at Risk for Diabetes) study, which highlights the effectiveness of the Company's Scout DS® NonInvasive Diabetes Screening Device.

Published: 25 July 2014
Written by Editor
TSX Venture   Project Update  
Read more: Miraculins Inc ( MOM )

Quidel Reports 2nd Quarter 2014 Financial Results

SAN DIEGO, CA--(July 22, 2014) - Quidel Corporation (QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the second quarter ended June 30, 2014.

Second Quarter 2014 Highlights:

  • Total revenues were $31.5 million compared to $29.7 million in the second quarter of 2013.
  • Reported GAAP EPS of $(0.20) per share compared to $(0.05) per share in the second quarter of 2013.
  • Received 510(k) clearance from the United States Food and Drug Administration (FDA) for Lyra™ molecular PCR assay for the detection of infections from Streptococcus groups A and C or G.
  • Received 510(k) clearance from the FDA for Lyra™ molecular PCR assay for the detection of Herpes Simplex Virus 1+2 and Varicella Zoster Virus.
  • Received CLIA waiver designation for Sofia® diagnostic test for Respiratory Syncytial Virus (RSV).
Published: 23 July 2014
Written by Editor
Nasdaq   Up on News  
Read more: Quidel Corporation ( QDEL )
  1. Miraculins Inc ( MOM )
  2. Nanosphere Inc ( NSPH )
  3. Biocept Inc (BIOC)
  4. Venaxis Inc ( APPY )
  5. BG Medicine Inc ( BGMD )